Trials / Conditions / Non-Muscle Invasive Bladder Urothelial Carcinoma

Non-Muscle Invasive Bladder Urothelial Carcinoma

13 registered clinical trials studyying Non-Muscle Invasive Bladder Urothelial Carcinoma — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With N NCT05521698	University of Wisconsin, Madison	Phase 1
Recruiting	Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladd NCT05962541	University of Roma La Sapienza	Phase 4
Not Yet Recruiting	A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. NCT07064863	Queen's University	Phase 1 / Phase 2
Recruiting	Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chem NCT06770582	National Cancer Institute (NCI)	Phase 2
Recruiting	A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer NCT06503614	John Sfakianos	Phase 2
Recruiting	Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma Af NCT06766266	First Affiliated Hospital of Chongqing Medical University	Phase 1
Recruiting	Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSIT NCT06396533	Fox Chase Cancer Center	—
Recruiting	A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer NCT05483868	Aura Biosciences	Phase 1
Unknown	Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which NCT04730232	Tianjin Medical University Second Hospital	Phase 2
Completed	Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer NCT05946369	Ain Shams University	—
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment ( NCT04164082	National Cancer Institute (NCI)	Phase 2
Completed	Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior Histo NCT06020807	Nucleix Ltd.	—
Recruiting	Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. NCT06167356	IRCCS San Raffaele	—